Hjem
Kenneth Dicksteins bilde

Kenneth Dickstein

Professor
  • E-postKenneth.Dickstein@uib.no
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) 2014. The relationship between markers of extracellular cardiac matrix turnover: Infarct healing and left ventricular remodelling following primary PCI in patients with first-time STEMI. European Heart Journal. 395-402.
  • Vis forfatter(e) 2014. The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patients. European Journal of Heart Failure. 289-299.
  • Vis forfatter(e) 2014. Repetitive use of levosimendan for treatment of chronic advanced heart failure: Clinical evidence, practical considerations, and perspectives: An expert panel consensus. International Journal of Cardiology. 360-367.
  • Vis forfatter(e) 2013. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. European Heart Journal. 30-38.
  • Vis forfatter(e) 2013. Sildenafil in Heart Failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design. European Journal of Heart Failure. 119-122.
  • Vis forfatter(e) 2013. Peripheral artery disease and outcomes after myocardial infarction: An individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. International Journal of Cardiology. 1094-1101.
  • Vis forfatter(e) 2013. Meta-analysis of symptomatic response attributable to the pacing component of cardiac resynchronization therapy. European Journal of Heart Failure. 1419-1428.
  • Vis forfatter(e) 2013. Intravenous immunoglobulin does not reduce left ventricular remodeling in patients with myocardial dysfunction during hospitalization after acute myocardial infarction. International Journal of Cardiology. 212-218.
  • Vis forfatter(e) 2013. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. European Journal of Heart Failure. 1267-1276.
  • Vis forfatter(e) 2013. Global variation in quality of care among patients hospitalized with acute heart failure in an international trial findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF). Circulation. Cardiovascular Quality and Outcomes. 534-542.
  • Vis forfatter(e) 2013. Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. International Journal of Cardiology. 729-735.
  • Vis forfatter(e) 2013. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. New England Journal of Medicine. 1395-1405.
  • Vis forfatter(e) 2013. Cardiac resynchronization therapy improves minute ventilation/carbon dioxide production slope and skeletal muscle capillary density without reversal of skeletal muscle pathology or inflammation. Europace. 857-864.
  • Vis forfatter(e) 2012. Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. European Journal of Heart Failure. 1257-1264.
  • Vis forfatter(e) 2012. Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. European Journal of Heart Failure. 1401-1409.
  • Vis forfatter(e) 2012. Myocardial Connective Tissue Growth Factor (CCN2/CTGF) Attenuates Left Ventricular Remodeling after Myocardial Infarction. PLOS ONE. 15 sider.
  • Vis forfatter(e) 2012. Increased interleukin-1 beta levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention. Journal of Internal Medicine. 267-276.
  • Vis forfatter(e) 2012. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic HeartFailure 2012 of the European Society of Cardiology. Developed in collaborationwith the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure. 803-869.
  • Vis forfatter(e) 2012. ESC Guidelines for the management of acute myocardial infarction in patientspresenting with ST-segment elevation. European Heart Journal. 2569-2619.
  • Vis forfatter(e) 2012. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic HeartFailure 2012 of the European Society of Cardiology. Developed in collaborationwith the Heart Failure Association (HFA) of the ESC. European Heart Journal. 1787-1847.
  • Vis forfatter(e) 2012. A multi-center, double-blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment. Chinese Medical Journal. 3868-3874.
  • Vis forfatter(e) 2012. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace. 1236-1286.
  • Vis forfatter(e) 2012. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm. 1524-1576.
  • Vis forfatter(e) 2011. The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. International Journal of Cardiology. 277-282.
  • Vis forfatter(e) 2011. Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 115-126.
  • Vis forfatter(e) 2011. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. European Journal of Heart Failure. 107-114.
  • Vis forfatter(e) 2010. Update of ESC guidelines regarding usage of devices in patients with heart failure-2010. Kardiologia polska. S475-S486.
  • Vis forfatter(e) 2010. The impact of the 2007 ESC-ACC-AHA-WHF Universal definition on the incidence and classification of acute myocardial infarction: A retrospective cohort study. International Journal of Cardiology. 228-233.
  • Vis forfatter(e) 2010. Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes Lessons Learned and Directions Forward. Circulation: Heart Failure. 314-325.
  • Vis forfatter(e) 2010. Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. European Journal of Heart Failure. 239-248.
  • Vis forfatter(e) 2010. 2010 Focused Update of ESC Guidelines on device therapy in heart failure. European Journal of Heart Failure. 1143-1153.
  • Vis forfatter(e) 2010. 2010 Focused Update of ESC Guidelines on device therapy in heart failure. Europace. 1526-1536.
  • Vis forfatter(e) 2009. The European cardiac resynchronization therapy survey. European Heart Journal. 2450-2460.
  • Vis forfatter(e) 2009. The Chemokine Network in Relation to Infarct Size and Left Ventricular Remodeling Following Acute Myocardial Infarction. American Journal of Cardiology. 1179-1183.
  • Vis forfatter(e) 2009. Six-Minute Walk Test and Cardiopulmonary Exercise Testing in Patients With Chronic Heart Failure A Comparative Analysis on Clinical and Prognostic Insights. Circulation: Heart Failure. 549-555.
  • Vis forfatter(e) 2009. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). American Heart Journal. 271-277.
  • Vis forfatter(e) 2009. Rationale and design of Ferinject((R)) Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. European Journal of Heart Failure. 1084-1091.
  • Vis forfatter(e) 2009. Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. European Heart Journal. 1331-1339.
  • Vis forfatter(e) 2009. Moderate alcohol consumption is associated with reduced long-term cardiovascular risk in patients following a complicated acute myocardial infarction. International Journal of Cardiology. 229-232.
  • Vis forfatter(e) 2009. Microvascular obstruction is a major determinant of infarct healing and subsequent left ventricular remodelling following primary percutaneous coronary intervention. European Heart Journal. 1978-1985.
  • Vis forfatter(e) 2009. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. European Heart Journal. 1229-1236.
  • Vis forfatter(e) 2009. Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008. European Journal of Heart Failure. 1143-1151.
  • Vis forfatter(e) 2009. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. New England Journal of Medicine. 2436-2448.
  • Vis forfatter(e) 2009. Erythropoietin levels in heart failure after an acute myocardial infarction: Determinants, prognostic value, and the effects of captopril versus losartan. American Heart Journal. 91-96.
  • Vis forfatter(e) 2009. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. The Lancet. 1840-1848.
  • Vis forfatter(e) 2009. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. European Heart Journal. 478-486.
  • Vis forfatter(e) 2009. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. European Heart Journal. 1187-1194.
  • Vis forfatter(e) 2009. C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. European Heart Journal. 1180-1186.
  • Vis forfatter(e) 2009. B-type natriuretic peptide is related to histological skeletal muscle abnormalities in patients with chronic heart failure. International Journal of Cardiology. 358-362.
  • Vis forfatter(e) 2008. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. The Lancet. 547-553.
  • Vis forfatter(e) 2008. Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. European Journal of Heart Failure. 140-148.
  • Vis forfatter(e) 2008. Effect of exercise training on chromogranin A and relationship to N-ANP and inflammatory cytokines in patients with chronic heart failure. International Journal of Cardiology. 117-120.
  • Vis forfatter(e) 2008. Design of the Heart failure Endpoint evaluation of AII-Antagonist Losartan (HEAAL) study in patients intolerant to ACE-inhibitor. European Journal of Heart Failure. 899-906.
  • Vis forfatter(e) 2008. A randomised trial of a pre-synaptic stimulator of DA(2)-dopaminergic and alpha(2)-adrenergic receptors on morbidity and mortality in patients with heart failure. European Journal of Heart Failure. 89-95.
  • Vis forfatter(e) 2007. Usefulness of either or both left and right bundle branch block at baseline or during follow-up for predicting death in patients following acute myocardial infarction. American Journal of Cardiology. 647-650.
  • Vis forfatter(e) 2007. Unrecognized glycometabolic disturbance as measured by hemoglobin A(1c) is associated with a poor outcome after acute myocardial infarction. American Heart Journal. 470-476.
  • Vis forfatter(e) 2007. Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: Relation to cardiac magnetic resonance imaging measures of left ventricular structure and function. Journal of Cardiac Failure. 843-849.
  • Vis forfatter(e) 2007. Effect of left ventricular scar size, location, and transmurality on left ventricular remodeling with healed myocardial infarction. American Journal of Cardiology. 1104-1114.
  • Vis forfatter(e) 2006. The impact of morbid events on survival following hospitalization for complicated myocardial infarction. European Journal of Heart Failure. 74-80.
  • Vis forfatter(e) 2006. The effect of altering haemodynamics on the plasma concentrations of natriuretic peptides in heart failure. European Journal of Heart Failure. 628-633.
  • Vis forfatter(e) 2006. Sex-based short- and long-term survival in patients following complicated myocardial infarction. European Heart Journal. 2177-2183.
  • Vis forfatter(e) 2006. Rapid implementation of therapeutic hypothermia in comatose out-of-hospital cardiac arrest survivors. Acta Anaesthesiologica Scandinavica. 1277-1283.
  • Vis forfatter(e) 2006. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. American Heart Journal. 927e1-927e6.
  • Vis forfatter(e) 2006. Mannose binding lectin and soluble Toll-lilke receptor 2 in heart failure following acute myocardial infarction. Journal of Cardiac Failure. 659-663.
  • Vis forfatter(e) 2005. Soluble CD40 ligand in acute and chronic heart failure. European Heart Journal. 1101-1107.
  • Vis forfatter(e) 2005. Soluble CD40 ligand in acute and chronic heart failure. European Heart Journal. 1101-1117.
  • Vis forfatter(e) 2005. Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. American Journal of Medicine. 752-758.
  • Vis forfatter(e) 2005. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAL experience. European Heart Journal. 350-356.
  • Vis forfatter(e) 2005. Plasma natriuretic peptides up to 2 years after acute myocardial infarction and relation to prognosis: an OPTIMAAL substudy. Journal of Cardiac Failure. 492-497.
  • Vis forfatter(e) 2005. Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients. Journal of the American College of Cardiology. 2018-2021.
  • Vis forfatter(e) 2005. Is eplerenone a cost-effective therapy for heart failure patients after myocardial infarction? Nature Clinical Practice Cardiovascular Medicine. 440-441.
  • Vis forfatter(e) 2005. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. European Heart Journal. 650-61.
  • Vis forfatter(e) 2005. Exercise training in congestive heart failure. A review of the current status. Minerva Cardioangiologica : a Journal on Cardiovascular Pathophysiology, Clinical Medicine and Therapy. 275-286.
  • Vis forfatter(e) 2005. Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). American Heart Journal. 123-131.
  • Vis forfatter(e) 2004. The data monitoring experience in the MOXCON trial. European Heart Journal. 174-178.
  • Vis forfatter(e) 2004. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. New England Journal of Medicine. 1285-1295.
  • Vis forfatter(e) 2004. Prognostic value of osteoprotegerin in heart failure following acute myocardial infarction. Journal of the American College of Cardiology. 1970-1976.
  • Vis forfatter(e) 2004. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. Journal of the American College of Cardiology. 1970-1976.
  • Vis forfatter(e) 2004. Effects of losartan and captopril on morbidity and mortality after acute MI. Cardiology Review. 23-29.
  • Vis forfatter(e) 2004. Effect of single doses of SLV306, an inhibitor of both neutral enclopepticlase and enclothelin-converting enzyme, on pulmonary pressures in congestive heart failure. American Journal of Cardiology. 237-240.
  • Vis forfatter(e) 2004. Effect of exercise training in patients with heart failure: a pilot study on autonomous balance assessed by heart rate variability. Journal of Cardiovascular Risk. 162-167.
  • Vis forfatter(e) 2004. Effect of exercise training in patients with heart failure: a pilot study on autonomic balance assessed by heart rate variability. Journal of Cardiovascular Risk. 162-167.
  • Vis forfatter(e) 2004. Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. American Journal of Cardiology. 603-606.
  • Vis forfatter(e) 2004. Comparison of mortality rates after acute myocardial infarction in smokers versus nonsmokers. American Journal of Cardiology. 632-636.
  • Vis forfatter(e) 2003. Prognostic usefulness of an increase of N-terminal proatrial natriuretic peptide during exercise in patients with chronic heart failure. American Journal of Cardiology. 91-94.
  • Vis forfatter(e) 2003. Prognostic usefulness of an increase in N-terminal proatrial natriuretic peptide during exercise in patients with chronic heart failure. American Journal of Cardiology. 91-94.
  • Vis forfatter(e) 2003. Plasma chromogranin A concentration as an indicator of long-term mortality after acute myocardial infarction. American Journal of Medicine. 25-30.
  • Vis forfatter(e) 2003. Neurohumoral inhibition in heart failure; is there no limit? European Heart Journal. 1705-1706.
  • Vis forfatter(e) 2003. N-terminal proatrial natriuretic peptide in primary care: relation to echocardiographic indices of cardiac function in mild to moderate cardiac disease. International Journal of Cardiology. 197-205.
  • Vis forfatter(e) 2003. N-terminal proatrial natriuretic peptide in primary care: relation to echocardiographic indices of cardiac function in mild to moderate cardiac disease. International Journal of Cardiology. 197-205.
  • Vis forfatter(e) 2003. Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. American Journal of Medicine. 25-30.
  • Vis forfatter(e) 2003. Association between plasma chromogranin A and long-term mortality after myocardial infarction. American Journal of Medicine. 25-30.
  • Vis forfatter(e) 2002. Prioritering av sykehusobduksjon. Tidsskrift for Den norske legeforening. 2787-2790.
  • Vis forfatter(e) 2002. How do heart failure patients die? European Heart Journal. D59-D65.
  • Vis forfatter(e) 2002. For the OPTIMAAL trial: losartan or captopril after acute myocardial infarction. The Lancet. 1885.
  • Vis forfatter(e) 2002. Effects of losatan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. The Lancet. 752-760.
  • Vis forfatter(e) 2002. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. The Lancet. 752-760.
  • Vis forfatter(e) 2002. Effect of exercise training on skeletal muscle fibre characteristics in men with chronic heart failure. Correlation between skeletal muscle alterations, cytokines and exercise capacity. International Journal of Cardiology. 25-32.
  • Vis forfatter(e) 2002. Characteristics and prognostic impact of plasma fibrin monomer (soluble fibrin) in patients with coronary artery disease. Blood Coagulation and Fibrinolysis. 301-308.
  • Vis forfatter(e) 2001. The role of losartan in the management of patients with heart failure. Clinical Therapeutics. 1456-1477.
  • Vis forfatter(e) 2001. How long should ACE inhibitors be given to patients following myocardial infarction: Implications of HOPE. Controlled Clinical Trials. 151-154.
  • Vis forfatter(e) 2001. Fibrin monomer (soluble fibrin) as a marker of coagulation activation in patients with acute chest pain syndromes. Clinical Chemistry.
  • Vis forfatter(e) 2001. Effect of simvastatin in preventing progression of carotid artery stenosis. American Journal of Cardiology. 643-646.
  • Vis forfatter(e) 2001. Effect of aerobic exercise training on plasma levels of tumor necosis factor alpha in patients with heart failure. American Journal of Cardiology. 805-808.
  • Vis forfatter(e) 2001. ELITE II and ValHeft; Together what do they tell us? Controlled Clinical Trials. 240-243.
  • Vis forfatter(e) 2001. Digitalis ved hjertesvikt - fortsatt et aktuelt behandlingsprinsipp? Tidsskrift for Den norske legeforening. 212-214.
  • Vis forfatter(e) 2001. Comparison of baseline data, initial course, and management: Losartan vs. Captopril following acute myocardial infarction (The OPTIMAAL Trial). American Journal of Cardiology. 766-771.
  • Vis forfatter(e) 2001. Comparison of baseline data, Initial course, and mannagment: Losartan Versus captopril following acute myocardial infarction (The OPTIMAAL Trial). American Journal of Cardiology. 766-771.
  • Vis forfatter(e) 2001. Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma. American Journal of Ophthalmology. 626-632.
  • Vis forfatter(e) 2001. Assessing the effect of exercise training in men with heart failure. Comparison of maximal, submaximal and endurance protocols. European Heart Journal. 684-692.
  • Vis forfatter(e) 2001. AllAs in congestive heart failure: Insights from ELITE II and ValHeft. Receptors in Cardiovascular Disease. 7.
  • Vis forfatter(e) 2000. The use of angiotensin II receptor antagonists in heart failure. Tidsskrift for Den norske legeforening. 817-821.
  • Vis forfatter(e) 2000. The Effects of Chronic, Sustained-release Moxonidine Therapy on Clinical and Neurohumoral Status in Patients with Heart Failure. International Journal of Cardiology. 167-176.
  • Vis forfatter(e) 2000. The Effects of Chronic, Sustained-release Moxonidine Therapy on Clinical and Neurohumoral Status in Patients with Heart Failure. International Journal of Cardiology. 167-176.
  • Vis forfatter(e) 2000. Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure: the Losartan Heart Failure Survival Study - ELITE II. The Lancet. 1582-1587.
  • Vis forfatter(e) 2000. Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure: the Losartan Heart Failure Survival Study - ELITE II. The Lancet. 1582-1587.
  • Vis forfatter(e) 2000. Plasma chromogranin A is an independent predictor of survival after acute myocardial infarction. European Heart Journal. 584.
  • Vis forfatter(e) 2000. Plasma brain natriuretic peptide as a prognostic indicator in patients with preserved left ventricular systolic function after acute myocardial infarction. Circulation. 609.
  • Vis forfatter(e) 2000. Pharmacotherapy following myocardial infarction - a review of current treatment practices. Exp Opin Pharmacother. 1105-1116.
  • Vis forfatter(e) 2000. Pharmacotherapy following myocardial infarction - a review of current treatment practices. Expert Opinion on Pharmacotherapy. 1105-1116.
  • Vis forfatter(e) 2000. Losartan vs. Captopril in patients following Acute Myocardial Infarction: The OPTIMAL Trial Design. Receptors in Cardiovascular Disease. 4-9.
  • Vis forfatter(e) 2000. Losartan vs. Captopril in patients following Acute Myocardial Infarction: The OPTIMAL Trial Design. Receptors in Cardiovascular Disease. 4-9.
  • Vis forfatter(e) 2000. Improvements in quality of life of symptomatic heart failure patients treated long-term with losartan and captopril: the ELITE II quality of life substudy. European Heart Journal. 464.
  • Vis forfatter(e) 2000. Exercise training in heart failure. Time to go beyond surrogate endpoints. European Journal of Heart Failure. 5-6.
  • Vis forfatter(e) 2000. Exercise training in heart failure. Time to go beyond surrogate endpoints. European Journal of Heart Failure. 5-6.
  • Vis forfatter(e) 2000. Er øyeblikkelig hjelp-innleggelser i medisinks avdeling avhengig av været? Tidsskrift for Den norske legeforening. 3678-3679.
  • Vis forfatter(e) 2000. Effects of moxonidine, a novel imidazoline agonist, on plasma norepinephrine in patients with congestive heart failure. Journal of the American College of Cardiology. 398-404.
  • Vis forfatter(e) 2000. Effects of moxonidine, a novel imidazoline agonist, on plasma norepinephrine in patients with congestive heart failure. Journal of the American College of Cardiology. 398-404.
  • Vis forfatter(e) 2000. Effects of exercise training on maximal and submaximal endurance capacity in men with congestive heart failure. European Journal of Heart Failure. In press.
  • Vis forfatter(e) 2000. Effect of simvastatin in preventing progression of carotid artery stenosis. American Journal of Cardiology. 17-20.
  • Vis forfatter(e) 2000. Effect of aerobic exercise training on cytokine levels in patients with congestive heart failure. European Heart Journal. 234.
  • Vis forfatter(e) 2000. Bruk av angiotensin II - reseptorblokkere ved hjertesvikt. Tidsskrift for Den norske legeforening. 817-821.
  • Vis forfatter(e) 2000. Are emergency medical admissions dependent on the weather? Tidsskrift for Den norske legeforening. 355-357.
  • Vis forfatter(e) 2000. Angiotensin II antagonists are superior to ACE inhibitors. David versus Golitah. European Journal of Heart Failure. 235-236.
  • Vis forfatter(e) 2000. Angiotensin II antagonists are superior to ACE inhibitors. David versus Golitah. European Journal of Heart Failure. 235-236.
  • Vis forfatter(e) 1999. Kronisk hjertesvikt - forslag til handlingsprogram. Tidsskrift for Den norske legeforening. 3427-3431.
  • Vis forfatter(e) 1999. Comparison of the effects of Losartan and Captopril on mortality in patients after acute myocardial infarction: The OPTIMAAL Trial Design. American Journal of Cardiology. 1-5.
  • Vis forfatter(e) 1997. Treatment of heart failure with beta-adrenergic blocking drugs. Tidsskrift for Den norske legeforening. 526-528.
  • Vis forfatter(e) 1997. Plasma N-terminal atrial natriuretic factor: a predictor of survival in patients with congestive heart failure. Journal of Cardiac Failure. 83-89.
  • Vis forfatter(e) 1997. Effects of angiotensin II receptor blockage on N- terminal proatrial natriuretic factor plasma levels in chronic heart failure. Journal of Cardiac Failure. 75-81.
  • Vis forfatter(e) 1997. Digitalis - et gammelt, men stadig aktuelt medikament. Therapia medica. 16-18.
  • Vis forfatter(e) 1997. Calcium channel blockers in heart failure. Tidsskrift for Den norske legeforening. 2329-2332.
  • Vis forfatter(e) 1997. Betablokkerbehandling av hjertesviktpasienter. Tidsskrift for Den norske legeforening. 526-528.
  • Vis forfatter(e) 1996. Pro-atrial natriuretisk faktor i plasma er prediktiv for klinisk status hos hjertesviktpasienter. Tidsskrift for Den norske legeforening. 1562-1566.
  • Vis forfatter(e) 1993. The effect of early converting enzyme inhibition on neurohumoral activycation in acute myocardial infarction. International Journal of Cardiology. 37-45.
Vitenskapelig foredrag
  • Vis forfatter(e) 2008. C-reactive protein, infarct size, microvascular obstruction and left ventricular remodeling following acute myocardial infarction.
  • Vis forfatter(e) 2005. Living with an implantable cardioverter defibrillator: A qualitative study from one Norwegian centre.
  • Vis forfatter(e) 2002. The role of angiotensin II antagonists in heart failure and following myocardial infarction.
  • Vis forfatter(e) 2002. State of the art management of myocardial infarction.
  • Vis forfatter(e) 2002. Results of recent trials in patients with heart failure following myocardial infarction.
  • Vis forfatter(e) 2002. Outpatient heart failure management programs – 4 models New markers of heart failure Determinants of long-term prognosis in heart failure Emerging therapies for heart failure.
  • Vis forfatter(e) 2002. Modern Aspects of Heart Failure Management. Recent Acheivements and Future Directions.
  • Vis forfatter(e) 2002. Controlling the course of disease in the post-myocardial infarction patient: the OPTIMAAL trial.
  • Vis forfatter(e) 2002. Comparison of the Effects of Losartan and Captopril on Mortality and Morbidity in patients following Acute Myocardial Infarction: The OPTIMAAL Trial.
  • Vis forfatter(e) 2002. Clinical implications of losartan in the OPTIMAAL study.
  • Vis forfatter(e) 2002. Beta-blockers should be withdrawn in decompensated heart failure patients.
  • Vis forfatter(e) 2002. Angiotensin II antagonists; are they established therapy in heart failure?
  • Vis forfatter(e) 2002. ARBs are as good as ACE inhibitors.
  • Vis forfatter(e) 2001. Effect of exercise training on muscle fibre characteristics in patients with heart failure.
  • Vis forfatter(e) 1996. N-terminal probrain natriuretic peptide - a new marker of cardiac function and prognosis.
Sammendrag/abstract
  • Vis forfatter(e) 2013. The association between heart rate, pulse pressure and clinical outcomes in 16503 patients with myocardial infarction complicated by signs of heart failure or left ventricular dysfunction. European Heart Journal. 349-349.
  • Vis forfatter(e) 2013. Early discharge (< 3 days) following primary PCI is safe in low risk patients. European Heart Journal. 246-246.
  • Vis forfatter(e) 2013. ESC Heart Failure Guidelines 2012-a review. Journal of Cardiac Failure. S106-S107.
  • Vis forfatter(e) 2010. Smokers spend shorter time in hospital than non-smokers following complicated AMI. European Heart Journal. 683-683.
  • Vis forfatter(e) 2010. Predicting Adverse Effects during Angiotensin Receptor Blocker Treatment in Heart Failure: Results from the HEAAL Trial. Journal of Cardiac Failure. S73-S74.
  • Vis forfatter(e) 2010. Peripheral artery disease as a predictor of outcome in high-risk MI patients: pooled analysis from the high risk MI database initiative (pooled data from CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT). European Heart Journal. 604-604.
  • Vis forfatter(e) 2010. NT-proBNP is a potent prognostic marker in patients with type 2 diabetes hospitalized for acute coronary syndrome - a DIGAMI 2 sub study. European Heart Journal. 514-515.
  • Vis forfatter(e) 2010. Myocardial connective tissue growth factor (CCN2/CTGF) attenuates left ventricular remodeling after myocardial infarction and prevents ischemic heart failure. European Heart Journal. 314-314.
  • Vis forfatter(e) 2010. Intravenous ferric carboxymaltose improves quality of life in patients with chronic heart failure and iron deficiency regardless the presence of anaemia: an analysis from the FAIR-HF study. European Heart Journal. 233-233.
  • Vis forfatter(e) 2010. Early increase in Stromelysin-1 levels is related to infarct size and predicts long-term LV remodelling following STEMI. European Heart Journal. 192-193.
  • Vis forfatter(e) 2010. Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Circulation. 2217-2217.
  • Vis forfatter(e) 2009. Circulating Markers of Collagen Turnover Following ST-Segment Elevation Myocardial Infarction and Primary Percutaneous Coronary Intervention Predict Infarct Size and Left Ventricular Volumes, Estimated by Serial Cardiac Magnetic Resonance Imaging for up to 1 Year. Circulation. S818-S818.
  • Vis forfatter(e) 2007. The relationship between N-terminal B-type natriuretic peptide and circulating markers of extracellular cardiac remodelling in patients following complicated myocardial infarction. European Journal of Heart Failure. 10-11.
  • Vis forfatter(e) 2004. What's new in the management of heart failure? Atherosclerosis Supplements.
  • Vis forfatter(e) 2004. Total mortality and sudden cardiac death are predicted by both left and right bundle branch block at baseline and during follow-up after complicated myocardial infarction. Circulation. A1032-A1032.
  • Vis forfatter(e) 2004. The relationship between the extent of myocardial scarring and left ventricular ejection fraction assessed by cardiac magnetic resonance in 57 patients with previous myocardial infarction. European Heart Journal. 599-599.
  • Vis forfatter(e) 2004. The longitudinal profile of markers of cardiac extracellular matrix turnover in patients following acute myocardial infarction. European Heart Journal.
  • Vis forfatter(e) 2004. Relative impact of renal function on circulating levels of brain-type natriuretic peptide an N-terminal-pro-brain-type natriuretic peptide in patients with postinfarction heart failure. European Heart Journal. 292-292.
  • Vis forfatter(e) 2004. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction. The OPTIMAL experience. European Heart Journal. 299-299.
  • Vis forfatter(e) 2004. Moderate alcohol use is associated with reduced cardiovascular risk in patients following complicated acute myocardial infarction. JACC. 1153-1173.
  • Vis forfatter(e) 2004. Hemoglobin levels predict survival and hospitalization after a complicated acute myocardial infarction: Results from the OPTIMAAL study. Circulation. 574-575.
  • Vis forfatter(e) 2004. Haemoglobin levels predict survival and hospitalisation after a complicated acute myocardial infarction: results from the OPTIMAAL study. European Heart Journal. 305-305.
  • Vis forfatter(e) 2004. Effect of hypo- and hyperkalemia on mode of death in patients with heart failure following myocardial infarction. European Heart Journal.
  • Vis forfatter(e) 2003. Serial high-sensitivity CRP measurements and long-term prognosis in postinfarction heart failure. The OPTIMAAL neurohormonal substudy. Circulation.
  • Vis forfatter(e) 2003. Serial high-sensitivity CRP measurements and long-term prognosis in post-infarction heart failure. The OPTIMAAL neurohormonal study. Circulation. 692-692.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) 2020. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 407-477.
  • Vis forfatter(e) 2019. Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. The Lancet. 1045-1055.
  • Vis forfatter(e) 2016. Telerehabilitation in heart failure patients: The evidence and the pitfalls. International Journal of Cardiology. 408-413.
  • Vis forfatter(e) 2015. The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations. International Journal of Cardiology. 256-264.
  • Vis forfatter(e) 2013. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. European Journal of Heart Failure. 1082-1094.
  • Vis forfatter(e) 2012. The High-Risk Myocardial Infarction Database Initiative. Progress in cardiovascular diseases. 362-366.
  • Vis forfatter(e) 2010. Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. European Journal of Heart Failure. 423-433.
  • Vis forfatter(e) 2008. Successful treatment of heart failure with devices requires collaboration. European Journal of Heart Failure. 1229-1235.
  • Vis forfatter(e) 2008. Overview of emerging pharmacologic agents for acute heart failure syndromes. European Journal of Heart Failure. 201-213.
  • Vis forfatter(e) 2008. Guidelines 2008 European Society of Cardiology on the diagnosis and treatment of acute and chronic heart failure. Kardiologia polska. S389-S454.
  • Vis forfatter(e) 2008. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal. 2388-442.
  • Vis forfatter(e) 2008. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Journal of Heart Failure. 933-989.
  • Vis forfatter(e) 2008. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. European Heart Journal. 2388-2442.
  • Vis forfatter(e) 2007. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 684-694.
  • Vis forfatter(e) 2005. Diagnosis and assessment of the heart failure patient: the cornerstone of effective management. European Journal of Heart Failure. 303-308.

Se fullstendig oversikt over publikasjoner i CRIStin.